Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Licences Biomarker for Blood Disorder from CeMM Vienna

Published: Thursday, April 10, 2014
Last Updated: Friday, April 11, 2014
Bookmark and Share
Company plans to develop a molecular diagnostic test for the calreticulin mutations.

QIAGEN N.V. has acquired an exclusive worldwide license to the biomarker calreticulin (CALR), whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms (MPNs), a group of blood disorders. QIAGEN licensed the technology from CeMM Vienna, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, whose scientists led a team that discovered the presence of mutations of the CALR protein in MPNs. QIAGEN plans to develop a molecular diagnostic test for the CALR mutations to offer each patient a clearer prognostic profile and to guide disease management. Development of a CALR diagnostic test is expected to be highly complementary to QIAGEN’s kits for a key mutation of the Janus kinase 2 (JAK2) gene.

Myeloproliferative neoplasms, a group of blood disorders involving overproduction of blood cells, are chronic diseases that can lead to several complications including thrombosis (blood clots) and in some cases difficult-to-treat acute leukemia. QIAGEN already has an exclusive license for the JAK2 V617F mutation, which is present in about 75% of patients with MPNs. According to an article published in the New England Journal of Medicine in December 2013 by the CeMM team led by Robert Kralovics, patients with CALR mutations suffer from a milder form of the disease than those with the JAK2V617F mutation, including a lower risk of thrombosis and a higher survival rate.

"This novel biomarker offers an exciting opportunity to broaden QIAGEN’s market-leading position in developing molecular diagnostics for the whole range of blood disorders. Together, the JAK2 and CALR biomarkers give us the ability to deliver personalized insights regarding diagnosis, prognosis and disease management for patients with myeloprofilerative disorders," said Peer M. Schatz, Chief Executive Officer of QIAGEN. “We are now looking forward to developing clinically proven tests for detection of CALR mutations on Rotor-Gene Q MDx, which is part of our industry-leading QIAsymphony family of automated platforms. CALR and JAK2 could also be promising targets for companion diagnostics as future drug candidates for these blood disorders may be linked to these biomarkers.”

Giulio Superti-Furga, Scientific Director of CeMM, said: “We estimate that up to 3 million people worldwide suffer from myeloproliferative neoplasms, and discovery of the CALR mutation by our CeMM and Medical University of Vienna research teams is a very important finding for the benefit of these patients. We are pleased to license the CALR biomarker to QIAGEN. The development of a standardized test will enable physicians to provide improved patient care. At the same time, our researchers will continue to advance the understanding of these diseases and to focus on developing novel treatment options. CeMM is constantly investing in basic research aimed at obtaining new insights in potential diagnostics and therapeutics.”

With the technologies licensed from CeMM, QIAGEN plans to develop commercial kits for the detection of CALR mutations and seek regulatory approvals for those products. These diagnostics will join the growing portfolio of kits designed to run on the QIAsymphony automation platform. In addition, the license from CeMM includes potential use of the biomarker in next-generation sequencing applications.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

QIAGEN Collaborates with Allele Frequency Community
QIAGEN providing secure bioinformatics infrastructure and software for research and clinical labs to contribute and gain insights from Allele Frequency Community.
Wednesday, February 25, 2015
QIAGEN Signs Ninth Master Collaboration Agreement for Companion Diagnostics
Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.
Thursday, November 13, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
FDA Approve QIAGEN PCR Kit For Use With Second Colorectal Cancer Drug
Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen’s Vectibix® (panitumumab) in treatment of metastatic colorectal cancer.
Tuesday, May 27, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Partners with Exosome Diagnostics
Molecular testing of biofluids promises unprecedented access to gene mutations, gene expression signatures and expression levels without costly, invasive tissue biopsies.
Wednesday, July 24, 2013
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics
Includes investment in new companion diagnostic that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients.
Tuesday, January 08, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-Sized U.S. Hospitals
Collaboration creates distribution channel to previously underserved market segment.
Tuesday, May 01, 2012
QIAGEN to Provide State-of-the-Art Technologies and Platforms for Gene Mutation Analysis and Sample Preparation Automation
Company announced that it has signed an agreement with Bio-X Center of Shanghai Jiao Tong University to open a joint translational medicine lab in Shanghai.
Thursday, March 22, 2012
QIAGEN to Supply Molecular Screening Solutions to Increase Safety of Blood Donations in Brazil
The supply agreement covers molecular sample and assay technologies for a national PCR-based blood screening program for HIV and HCV.
Friday, June 05, 2009
QIAGEN to Supply Molecular Screening Solutions to Increase Safety of Blood Donations in Brazil
The agreement to supply molecular sample and assay technologies for a PCR-based blood screening program for HIV HCV in Brazil.
Friday, May 29, 2009
QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu
German Bernhard Nocht Institute and Spanish Reference Laboratory detect infections with the H1N1 strain using QIAGEN’s artus influenza test.
Monday, May 04, 2009
Scientific News
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
Scientists Identify Schizophrenia’s “Rosetta Stone” Gene
Scientists have identified a critical function of what they believe to be schizophrenia’s “Rosetta Stone” gene that could hold the key to decoding the function of all genes involved in the disease.
Could a simple saliva test detect Alzheimer's?
Researchers have presented findings suggesting that a simple, non-invasive diagnostic for Alzheimer's could be within reach.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
AncestryDNA and Calico to Research the Genetics of Human Lifespan
Collaboration will analyze family history and genetics to facilitate development of cutting-edge therapeutics.
Gene Variation Identified for Teen Binge-Eating
Researchers have identified a gene variant which can lead to teenage binge eating, they hope that their work will inform the development of future preventative measures.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
Researchers at the Aortic Institute at Yale have tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care.
Facebook for the Proteome
Researchers have developed a network for describing protein-protein interactions that can then be used to examine protein interactions that may have biological or clinical significance.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!